Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 12
- Registration Number
- NCT00000706
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 120
- Registration Number
- NCT00000682
- Locations
- 🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸USC CRS, Los Angeles, California, United States
🇺🇸Ucsd, Avrc Crs, San Diego, California, United States
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Registration Number
- NCT00002045
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 168
- Registration Number
- NCT00000755
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Stanford CRS, Palo Alto, California, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1292
- Registration Number
- NCT00000781
- Locations
- 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States
🇵🇷Univ of Puerto Rico, San Juan, Puerto Rico
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 36
- Registration Number
- NCT00000987
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 80
- Registration Number
- NCT00000657
- Locations
- 🇺🇸
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 48
- Registration Number
- NCT00000696
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001048
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 60
- Registration Number
- NCT00000864
- Locations
- 🇺🇸
Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
🇺🇸Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States
🇵🇷San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.